Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Type 1 selected

Type

Guidance programme

Showing 101 to 110 of 113

TitleTypeExpected publication date
Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]Technology appraisal guidanceTBC
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]Technology appraisal guidanceTBC
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]Technology appraisal guidanceTBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]Technology appraisal guidanceTBC
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]Technology appraisal guidanceTBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]Technology appraisal guidance
Treatments for non-small-cell lung cancer [ID6234]Technology appraisal guidanceTBC
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]Technology appraisal guidanceTBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All